Fact CheckerSign in

NCT07686198Not yet recruitingPhase 2/3

Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms

A Randomized, Double-Blind, Vehicle-Controlled, Split-Arm Study of Twice Daily Re-Q Pro-Longevity Serum in Combination With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms

Source: ClinicalTrials.gov · Last updated 7 Jul 2026

Brief summary (registry, in English)

The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
20 (estimated)
First submitted
30 Jun 2026
Start date
10 Jul 2026
Primary completion date
10 Nov 2026
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
NCT number
NCT07686198

What you commit to

  • Study type: Interventional · Phase 2/3
  • Planned participants: 20
  • From 10 Jul 2026 to the primary completion date, 10 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with dark hair in the treatment area who are unwilling to shave the treated area prior to IPL treatments or who are unwilling to proceed knowing IPL will eliminate at least 50% of the hairs in the treatment area
  • A suntan in the treatment area or use of sunless tanner/spray-tan in the treatment areas 4 weeks prior to study treatment
  • Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation on the treatment area within 30 days prior to treatment and during the study period.
  • Use of GLP-1 medications or metformin within 3 months prior to enrollment
  • Current or recent use (within the past 3 months) of systemic immunosuppressive medications.
  • Active smoking tobacco or use of nicotine-containing products within 6 months prior to enrollment.
  • Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.

Other illness

  • Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
  • History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).
  • Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.
  • Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
  • History of keloids or scarring/tattoos in the treatment area

Other

  • Pregnancy, plans to become pregnant during the study period, or current breastfeeding.
  • Unwillingness to refrain from undergoing any additional aesthetic treatments to the arms (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.

Who the study is looking for

  • Female participants aged 50 to 80 years.
  • Fitzpatrick skin types I-IV.
  • Moderate to severe photodamage and crepiness on the arms, based on clinical evaluation, including fine wrinkling, coarse wrinkling, photodamage, and a global assessment as assessed with the 10-point Dermatologic Assessment Form and Photographic Scale
  • Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
  • Willing to sign an informed consent form and photography release for research, publication, and/or commercial use.
  • In good general health as determined by the investigator based on medical history and clinical judgment.
  • Willing to maintain the study skincare regimen and refrain from introducing new topical or procedural treatments to the forearms during the study period.
  • Negative urine pregnancy test at all visits for participants of childbearing potential.
  • Participants must be of non-childbearing potential, defined as: a. History of hysterectomy or bilateral oophorectomy, or b. No menses for at least 12 consecutive months without an alternative medical cause. Or, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include: i. Oral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) ii. Intrauterine coil iii. Bilateral tubal ligation iv. Hysterectomy v. Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) vi. Abstinence (must agree to use a barrier method if sexual activity begins during the study) vii. Partner with a vasectomy (if not, participant must agree to use a barrier method)

Age in the registry: 50 years to 80 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
West Dermatology Research Center/Cosmetic Laser Dermatology
Coordinator of this site? Confirm its status
San DiegoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.